Pharmacy news

Find pharmacy-related safety alerts, drug recall and new generic drug announcements and other medication information.

Drug recall

Drug recall notice for Hizentra 20% (10 g/50 mL

Drug recall

Drug recall notice for irbesartan tablets

Drug recall

Drug recall notice for Glucagon Emergency Kit

Pharmacy news bulletins available on the portal

For a list of pharmacy news bulletins, pharmacists may sign in to the Pharmacist Portal. If you do not have access, you can register for a new account.

Notifications and preauthorizations

Formulary changes for generic Ventolin HFA

Formulary changes for generic Zytiga

Drug recalls

Drug recall notice for Lotrimin AF and Tinactin spray products

Drug recall notice for Ruzurgi (amifampridine) 10 mg tablets

Drug recall notice for Chantix^® (varenicline) tablets

Drug recall notice for NP Thyroid tablets

Drug recall notice for metformin extended-release products

Drug recall notice for Nature-Throid and WP Thyroid tablets

Drug recall notice for Belviq, Belviq XR (lorcaserin)

Drug recall notice for Taro Pharmaceuticals phenytoin oral suspension

Drug recall notice for nizatidine capsules

Market withdrawal of all ranitidine products

Drug recall notice for Natpara

Impact of ongoing angiotensin II receptor blocker drug recalls

Additional notifications

Information about the use of ivermectin and COVID-19

The Centers for Disease Control and Prevention has released a health advisory regarding the rapid increase in ivermectin prescriptions and reports of severe illness associated with the use of products containing ivermectin to prevent and treat COVID-19.

Please see this notice, PDF for more information.

Information about the launch of generic Copaxone

Effective Jan. 1, 2022, generic Copaxone (glatiramer acetate) is not covered under Humana’s Basic and Walmart Value Part D plans. Brand-name Copaxone will continue to be covered and can be filled for the patient.

Prescribers with questions regarding this medication may call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.

Generic Copaxone FAQs, PDF

Updates could mean new requirements for Humana members

Beginning Jan. 1, 2022, certain drugs will have new limitations or will require utilization management (e.g., prior authorization [PA] requirements, step therapy [ST] modifications and nonformulary [NF] changes) under the Humana commercial and Medicare formularies for the 2022 plan year.

These changes could mean higher costs or new requirements for Humana members who use these drugs. Humana encourages the use of generic and cost-effective brand medications whenever possible. Depending on the member’s plan, Humana also may make positive and negative midyear changes for both commercial and Medicare formularies.

Information about the launch of generic Durezol

Effective Oct. 1, 2021, generic Durezol (difluprednate) is not covered by Humana’s Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Durezol will continue to be covered and can be filled for the patient.

Prescribers with questions regarding this may call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.

Generic Durezol FAQs, opens in new window

Information about the launch of generic Mitigare

Effective Jan. 1, 2021, generic Mitigare (colchicine capsule) is not covered or may require step therapy on Humana’s Medicare Advantage prescription drug, Medicare Part D and commercial (including RxAdvantage) plans; brand Mitigare will continue to be covered and can be filled for the patient.

Prescribers with questions regarding this may call 800-555-CLIN (800-555-2546), Monday through Friday, 8 a.m. to 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.

Generic Mitigare FAQs, PDF opens in new window

Information about the launch of generic Vascepa

Effective Nov. 7, 2020, generic Vascepa (icosapent) is not covered on Humana’s Medicare Advantage prescription drug and Part D plans; brand Vascepa will continue to be covered and can be filled for the patient.